pulmonary edema/edema

TECHNICAL FIELD This document pertains generally to medical systems, devices, or methods, and more particularly, but not by way of limitation, to systems and methods for monitoring pulmonary edema. BACKGROUND One hallmark of heart failure (HF) in a subject is congestion, more commonly referred to as

CROSS REFERENCE TO RELATED APPLICATIONS Applicant claims priority under 35 U.S.C. .sctn.119 of German Application No. 103 52 692.7 filed Nov. 12, 2003. Applicant also claims priority under 35 U.S.C. .sctn.365 of PCT/EP2004/012363 filed Nov. 2, 2004. The international application under PCT article

The present invention relates to novel therapeutic composition, particularly useful against acute pulmonary edema, shock caused by bacterial endotoxins, hyperfibrinolysis and anaphylactic shock. More specifically, the present invention relates to esters of L-arginine. Many esters of L-arginine are

FIELD OF THE INVENTION The invention generally relates to implantable medical devices, such as pacemakers or implantable cardioverter/defibrillators (ICDs), and in particular to techniques for measuring left ventricular end diastolic pressure (LV EDP) and for detecting the onset of heart failure and

TECHNICAL FIELD The invention relates to medical devices, and more particularly, to medical devices that sense cardiac electrical signals. BACKGROUND Heart failure refers to the heart's inability to keep up with the demands made upon it. Congestive heart failure refers to an inability of the heart

TECHNICAL FIELD This application relates generally to medical applications, and to detection of acute decompensation and pulmonary-related conditions. BACKGROUND The health of many patients who have had a heart attack may deteriorate over time due to progressive heart failure. For example, a heart

CROSS-REFERENCE TO RELATED APPLICATION This patent application is related to U.S. patent application, entitled "IMPROVED SENSITIVITY AND SPECIFICITY OF PULMONARY EDEMA DETECTION WHEN USING TRANSTHORACIC IMPEDANCE," filed even date herewith Ser. No. 11/126,723 which is hereby incorporated by

CROSS-REFERENCE TO RELATED APPLICATION This patent application is related to U.S. Pat. Application Ser. No. 11/126,689, entitled "ENHANCEMENTS TO THE DETECTION OF PULMONARY EDEMA WHEN USING TRANSTHORACIC IMPEDANCE," filed May 11, 2005, which is hereby incorporated by reference in its

TECHNICAL FIELD This patent document pertains generally to medical systems, devices, and methods, and more particularly, but not by way of limitation, to medical systems, devices, and methods for the detection of pulmonary edema using thoracic impedance. BACKGROUND Variations in how much fluid is

FIELD The present disclosure relates generally to systems and methods for treating pulmonary edema. BACKGROUND The lymphatic system is part of the circulatory system in conjunction with the arterial and venous systems. A primary function of the lymphatic system is to drain excessive interstitial

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to implantable medical devices, such as cardiac pacemakers and implantable cardioverter/defibrillators, and in particular to an improved method and an implantable medical device for assessing a degree of

CROSS REFERENCE TO RELATED APPLICATIONS This application is related to U.S. Pat. No. 7,676,260 Ser. No. 11/740,733, filed Apr. 26, 2007, titled "Implantable Cardiac Stimulation Device That Monitors Progression and Regression of Heart Disease Responsive to Differences in Averaged Electrograms and

BACKGROUND OF THE INVENTION Methods and compositions are provided for gene therapy for pulmonary edema by the transfer of Na,K-ATPase subunit genes to lung epithelial cells for the purpose of increasing levels of Na, K-ATPase in vivo. Cardiogenic and non-cardiogenic pulmonary edema affect millions

BACKGROUND OF THE INVENTION INOmax.RTM., (nitric oxide) for inhalation is an approved drug product for the treatment of term and near-term (>34 weeks gestation) neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. The use of

CROSS-REFERENCE TO RELATED APPLICATIONS This application is related to the following commonly assigned U.S. Patent Applications, each of which is incorporated herein by references: U.S. patent application Ser. No. 11/863,516, entitled "Use of Cardiogenic Impedance Waveform Morphology to Analyze